Compare NNDM & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNDM | CAPR |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.7M | 584.9M |
| IPO Year | 2015 | 2011 |
| Metric | NNDM | CAPR |
|---|---|---|
| Price | $1.19 | $8.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $27.25 |
| AVG Volume (30 Days) | 1.2M | ★ 3.6M |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $102,437,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.00 | $85.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 77.30 | N/A |
| 52 Week Low | $1.19 | $2.96 |
| 52 Week High | $2.32 | $40.37 |
| Indicator | NNDM | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 28.94 | 50.24 |
| Support Level | N/A | $7.78 |
| Resistance Level | $1.62 | $10.42 |
| Average True Range (ATR) | 0.06 | 1.01 |
| MACD | -0.01 | 0.23 |
| Stochastic Oscillator | 4.53 | 45.99 |
Nano Dimension Ltd provides industrial manufacturing solutions for the design-to-manufacturing of electronics and mechanical parts. These solutions are based on a combination of hardware, software, and materials science technologies. The solutions include industrial machinery, such as those for additive manufacturing, surface-mount technology, and industrial inkjet printing, along with software for design, simulation, and manufacturing management, as well as materials or consumables that are used by the machinery. These solutions are used by industrial customers in aerospace & defense, automotive, electronics, medical, research, and academia, along with government organizations.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.